t o baseline level by 24 hours. IL-la does not affect TNF receptor ligand binding affinity. A kinetic study comparing IL-l/ TNF synergistic induction of growth factor secretion with IL-la induction of TNF receptors shows that these events occur in parallel. In contrast with the induction of TNF receptors by IL-la, treatment with TNFa has no effect on either the number of IL-l receptors expressed by CDCL cells or IL-1 receptor ligand binding affinity. Brief treatment of IL"la/ TNFa-stimulated CDCL cells with cycloheximide before receptor induction reduces the synergistic increase in growth factor mRNA by 4 0 % t o 60% compared with cells not treated with CHX. Taken together, these results raise the possibility that IL-la cross-induction of TNF receptors may contribute t o the biochemical mechanisms underlying the synergistic stimulation of G-CSF and GM-CSF production by IL-la and TNFa. 0 1995 by The American Society of Hematology.
possible consequence of this apparent evolutionary convergence is that stimulation with IL-1 versus TNF could theoretically result in subtly distinct physiologic responses. However, in many cases, both TNF and IL-1 appear to be triggered by a common afferent signal. A second interesting possibility is that IL-1 and TNF actually work synergistically on at least some of their target cells. This molecular scenario would result in a significant expansion of the range of physiologic responses only at the cells that were targets for this synergy.
We have recently found that IL-la and TNFa synergize to stimulate cultured normal human BM stromal cells and a clonally derived human BM cell strain (CDCL) to secrete the myeloid colony-stimulating factors G-CSF and GM-CSF.I7 These results suggested that the apparently overlapping roles of IL-la and TNFa in stimulating myelopoiesis were actually two isolated components of a system characterized by powerful biochemical synergy. The biochemical mechanism by which this synergy occurred was not explored.
Recent studies in other systems suggest that physiologically convergent cytokines may interact at the level of cell surface receptor^.".'^ In instances where synergy has been observed between two or more cytokines, investigators have found an increase in expression of receptors for one of the cytokines involved. On the other hand, combinations of cytokines with either additive or contrasting physiologic effects generally did not show evidence for cross-regulation at the level of cell surface receptors.
In the present study, we have therefore sought to evaluate receptor cross-regulation as a possible mechanism for IL-l/ TNF synergistic induction of GM-CSF and G-CSF production by BM stromal cells. We have measured the number and affinity of IL-1 and TNF receptors in CDCL cells, clonally derived from human BM stromal cells before and after treatment with either or both inflammatory monokines. Our results show that treatment of CDCL cells with IL-la results in the induction of TNF receptors. This induction parallels the synergistic induction of myeloid-CSF mRNA accumula- , and 50% fresh medium exchange twice weekly, removing nonadherent cells with each exchange. Cultures were maintained at 37°C in a humidified environment under 5% CO,. Only early passaged (2 to 8 passages) BM stromal cells were used in the experiments described in this study. Experimental cultures were seeded at low density (1 X IO4 cells/mL) in six-well tissue culture plates (Costar, Cambridge, MA), and grown to visual confluence before initiation of experimental conditions. CDCL cells. Cultures of stroma-derived cell strains were established as previously described." Briefly, stromal cell cultures maintained in vitamin and amino acid-enriched McCoy's 5A medium, supplemented with 12.5% FBS, 12.5% HS, 0.036% hydrocortisone, and 1% Pen/Strep were trypsinized and pIated at low density (25 to 30 X IO3 cell/mL) in 2.5% methylcellulose supplemented with ILla (25 U/mL) and TNF-a (100 U/mL). After 2 weeks, colonies are plucked from the methylcellulose medium and added to liquid medium in the presence of basic-fibroblast growth factor (l0 ng/mL) to reestablish adherent cell cultures. Only early passaged (4 to 10 passages) CDCL cells were used in the experiments described in this study. Experimental cultures were seeded at low density (1 X lo4 cells/mL) in six-well tissue culture plates (Costar, Cambridge, MA), or T-25 cm2 flasks (Corning Inc, Coming, NY) and grown to visual confluence before initiation of experimental conditions.
Cytokines. Recombinant human IL-la and TNF-a were obtained from R & D Systems (Minneapolis, MN).
Anti-TNF receptor monoclonal antibodies (MoAbs). The anti-TNF receptor MoAbs htr-9 and utr-l were kindly provided by Dr M. Brockhaus (Hoffman-La Roche, Basel, Switzerland). htr-9 and utr-l uniquely bind to the 55-kD and 75-kD TNF receptors, respectively.
Secreted colony-stimulating factor assays. GM-CSF and G-CSF concentrations in experimental culture supernatants were determined by enzyme-linked immunoabsorbant assay (ELISA) (R & D Systems). ELISA optical densities were measured and analyzed by an ELISA plate reader (Molecular Devices Corp, Menlo Park, CA) interfaced with a personal computer using the Softmax program (Molecular Devices Corp). The ranges of cytokine detection in the ELISA were 1.5 to 750 pg/mL (GM-CSF) and 7.2 to 5,000 pg/mL GM-CSF and G-CSF mRNA analysis by Northern blot. Total RNA was isolated from confluent CDCL cell cultures maintained under one of the experimental conditions described earlier using a commercial kit, RNA Stat-60 (Tel-Test B, Inc, Friendwood, TX). Thirty-five micrograms of RNA per lane was fractionated under (G-CSF). @mL denatured and sheared salmon sperm DNA. Blots were hybridized at 42°C for 16 hours, washed twice at room temperature in 2 x SSC (Ix SSC = 0.15 m o a NaCVO.015 m o m NaCitrate, pH 7)/0.1% SDS, and then twice at 55°C in 0.1 X SSC/O.l% SDS. The GM-CSF probe is a 700-bp EcoRI-HindIII cDNA fragment and the G-CSF probe is 520-bp EcoRI cDNA fragment. DNA probes (25 ng) were labeled with [a-3zP]-deoxycytidine triphosphate (dCTP) (DuPont-NEN, Wilmington, DE) using the Hexaprime random primed labeling kit (Boehringer Mannheim, Indianapolis, IN). For autoradiographs, XOMAT x-ray film (Eastman Kodak, Rochester, NY) was exposed to the blots with intensifying screens at -80°C for 4 to 1 0 0 hours. Messenger RNA band intensities were quantified using an image analysis system (Molecular Dynamics, Sunnyvale, CA).
'"I-IL-la and '2'I-TNFa binding assays. Direct binding of iodine-125-labeled L -l a and TNF-a (DuPont-NEN) to CDCL stromal cells was performed by equilibrium binding at 20°C. CDCL cells were grown to confluence in six-well tissue culture plates (Costar). The medium was removed from each well and replaced with 0.8 mL of binding buffer (IMDM, 5% FCS, 0.2% NaN3) containing measured amounts of IZ5I-IL-la or '=I-TNF-a with or without a 50-fold excess of unlabeled ligand. The plates were then incubated at 20°C until binding equilibrium was achieved (10 hours for lZSI-IL-la, and 90 minutes for "'1-TNF-a). After the incubation period was completed, the supernatants were aspirated off and each well was washed three times with phosphate-buffered saline. To determine the number of bound counts, the cell monolayers were then solubilized with the addition of 1 mL of 2.5 moVL NaOH per well. The plates were then allowed to incubate at room temperature for 15 minutes for efficient solubilization of the cell monolayers. The solubilization fluid containing the bound counts was then transferred from each well to a 12-X 75-mm pyrex glass tube (Coming Inc) and counted in a gamma counter (Beckman Instruments, Fullerton, CA). The number of counts bound in the presence of excess unlabeled ligand was taken as a measure of nonspecific binding. The specific counts bound were calculated by subtracting the number of nonspecific counts bound from the total number of counts bound. Analysis of saturation binding isotherms and Scatchard transformation of specific binding data were performed using the INPLOT program (Graphpad, San Diego, CA).
RESULTS
IL-la and TNFa synergistically induce GM-CSF and G-CSF mRNA. Previous studies showed that L -l a and TNFa synergize to induce the secretion of GM-CSF and G-CSF from cultured human BM stromal cells, resulting in secreted CSF levels 5 to 10-fold greater than that of either cytokine alone. Similar synergistic stimulation was observed when assayed on CDCL cells, with 50-to 100-fold higher levels of G-CSF and GM-CSF secreted after stimulation by both IL-la and TNFa than with either cytokine alone." A kinetic analysis of growth factor secretion by IL-lamTNFa costimulated cells showed that additive levels were reached after 12 hours of stimulation, while clearly synergistic levels were achieved after 24 hours.
In the present experiments, Northern blot analysis of total
For personal use only. on June 3, 2017. by guest www.bloodjournal.org From cellular RNA isolated from CDCL cells treated with either IL-la, TNFa, or the two cytokines together, showed a time course for induction of growth factor mRNA similar to that observed with secreted proteins. That is, only slightly greater than additive levels were reached after cells were treated for 12 hours with L l a and TNF together, whereas synergistic levels were reached after 24 hours (Fig I, A and B) . Also, similar to the pattern observed with secreted proteins, the magnitude of mRNA induction was significantly greater for G-CSF than for GM-CSF. The relative degree of increase of the GM-and G-CSF mRNAs in IL-IamF-a-treated cells after 24 hours were similar, 22-to 43-fold and 27-to 54-fold, respectively, compared with either cytokine alone. These results show that the synergistic stimulation of GM-CSF and G-CSF secretion by CDCL cells is accompanied by a synergistic increase in growth factor messenger RNA as well.
Cycloheximide inhibits IL-la/TNF-a synergistic induction of cytokine mRNA. In the above experiment, it was found that IL-la and TNF-a synergistically induce GM-CSF and G-CSF mRNA in CDCL stromal cells. Treating CDCL cells with the protein synthesis inhibitor cycloheximide (CHX) before detection of synergistic increases in mRNA levels, caused a 50% to 60% decrease in the degree of synergistic induction compared to the levels in costimulated cultures not treated with CHX (Fig 2) . Interestingly, the decrease in the synergistic induction of growth factor mRNAs in CHXtreated cells occurred despite a sixfold increase in the level of GM-CSF mRNA from cells treated with IL-la alone. Thus in the presence of CHX, the net effect of treatment with IL-la together with TNF-a was only additive compared with the induction caused by either cytokine alone. Therefore, these data show that new protein synthesis is required for IL-la/TNF-a synergy.
IL-la increases expression of TNF receptors by CDCL stromal cells. One possible mechanism for IL-1aITNF-a synergistic stimulation of GM-CSF and G-CSF production by CDCL cells could be increased sensitization to the activity of one cytokine as the indirect result of the activity of the second cytokine. For example, one cytokine could stimulate an increase in either the number of receptors that bind the other cytokine or stimulate an increase in the other cytokine's receptor ligand affinity. To determine whether treatment with TNF-a causes a change in the expression of ILl receptors by CDCL cells, we analyzed specific binding of '2sI-IL-la to CDCL cells treated with TNF-a for various intervals up to 24 hours. There was no significant difference in the specific binding of '2'I-IL-la to TNF-a-treated cells compared with binding to cells that were not treated during the interval of synergistic build-up of either secreted protein or steady-state mRNA. (Fig 3) . Nor did an analysis of a I2'I-IL-la saturation binding curve of cells treated with TNF-a for 12 hours show any change in ligand-binding affinity compared with cells that were not treated with TNF-a (Fig  4) . A Scatchard plot of the saturation binding curves from CDCL cells treated and untreated with TNF-a showed that they express a low number of high-affinity IL-I receptors (-200 receptorskell with a binding affinity, kd = 16 to 26 X IO-'* moVL). These results show that TNF-a crossregulation of IL-I receptors is not a component in the mechanism of IL-Ia/TNF-a synergy. We next asked whether IL-la had any effect on the expression of TNF receptors. For these experiments we analyzed specific binding of I2'I-TNF-a to IL-la-treated CDCL cells at various intervals up to 24 hours as described before. Treatment of CDCL cells with IL-la initially caused a decrease in "'I-TNF-a specific binding, reaching a nadir after 3 hours at 70% to 75% of untreated cells. Subsequently, "'I-TNF-a-specific binding increased, reaching a maximum at 180% of the specific binding observed in untreated cells. The peak in "'I-TNF-a specific binding was observed Cycloheximide inhibition of cytokine induction of growth factor mRNA. Total RNA was isolated from CDCL cultures that were not treated (lane 1) or treated with IL-la (25 UlmL), TNF-a 1100 U/ mL), or IL-la plus TNF-a for 24 hours. Total RNA was isolated from a second set of cultures that were treated the same except that cycloheximide (20 pglmL) was added after 4.5 hours (lanes 5 through 7). After incubation for 90 minutes with cycloheximide, all the media were removed and replaced with the original media. All cultures were incubated for a total of 24 hours. Each lane was loaded with 35 p g of total RNA. Membranes were hybridized with cDNAs for GM-CSF randomly labeled with "P-dCTP. RNA loading concentrations were normalized against glyceraldehyde phosphate dehydrogenase (GAPDH). Band intensities were analyzed with a phosphor-imaging system and represented as percent of control (bottom panels).
at 6 hours after the start of IL-la treatment and gradually returned to near baseline level over the next 18 hours (Fig  5) . Analysis of "'I-TNF-a saturation binding curve and Scatchard plot of untreated cells showed that CDCL cells express a relatively low number of high-affinity TNF receptors (-1,450 receptorskell with binding affinity, kd = 2.5 X IO"" mol/L). However, treatment with IL-la for 6 hours resulted in a significant increase in the number of receptors on the cell surface up to -4,500, but did not change receptor binding affinity (Fig 6, A and B) . These data indicate that IL-1 a induces the increased expression of TNF receptors on CDCL cells, with peak induction at 6 hours. However, we note that stimulation of CDCL cells with IL-la failed to induce the expression of TNF-a mRNA or secretion of TNF- caused by a presentation of previously sequestered receptors or was the result of newly synthesized receptor protein, CHX was added to cultures of IL-la-treated CDCL cells before the time when increased TNF receptors are detected on the cell surface. Specifically, CHX was added to cultures that had already been treated with IL-la for 4.5 hours and cells were then further incubated in the presence of both IL-la and CHX for 90 minutes. Under these conditions, CHX completely prevented induction of TNF receptors by IL-la (Fig  7) . The CHX-treated cells remained viable and were able to be passaged subsequently to the same degree of confluence as untreated cultures (data not shown). These data show that the increase in "'1-TNF-a specific binding to IL-la-treated CDCL cells, like the IL-la/TNF-a synergistic induction of GM-CSF and G-CSF mRNA itself, is dependent on de novo protein synthesis. 2 $2" synthesis. To determine whether the increase in TNF remental period. These cultures were used as controls for degree of synergistic induction in the experimental cultures (Fig 8A) . If the IL-la-induced increase of TNF receptors was associated with IL-l/TNF synergy, then one would expect to see a level of stimulation of the 6-hour and, possibly, the 12-hour cultures, that was comparable with the degree of stimulation in the cultures that were stimulated with IL- Each data point is given es the percent of control and represents the mean f SD of triplicate determinations. of that found in cultures that were costimulated with IL-la and TNF-a for the entire 96-hour period (Fig 8, B and C) . In contrast, the cultures that were pretreated for 24 hours with IL-la before the addition of TNF-a secreted growth factor into the culture supernatant to a level only 50% to 60% of that found in the 96-hour costimulated cultures. These data show the IL-la/TNF-a synergistic stimulation of GM-CSF and G-CSF secretion by CDCL stromal cells occurs in parallel with IL-la induction of TNF receptors.
IL-IwTNF
CDCL cells express both types of TNF receptors. Two distinct forms of TNF receptors have been cloned and characterized. These 55-kD (p55) and 75-kD (p75) receptors are expressed to varying degrees on different cell types and mediate different TNF biologic activities2' Using MoAbs that specifically recognize either the 55-kD or 75-kD receptor,20 we determined that CDCL cells express both forms of TNF receptors (Fig 9) . The relative abundance of the two receptors forms on the surface of CDCL cells was approximately 60% p55 and 40% p75.
IL-la upregulates expression of the 75-kD receptor. We next sought to determine if the increase in '251-TNF-a specific binding was the result of an increase in the number of one or both receptor types. Replicate cultures of CDCL cells were treated with IL-la (25 U/mL) for 6, 12, or 24 hours and the specific binding of '''I-TNF-CY was determined. In a parallel experiment, IL-la-treated cultures were preincubated with saturating amounts (10 &mL) of htr-9 or utr-l antibodies before adding 'Z51-TNF-a. The reduction in specific binding of radio ligand was then determined. The data presented in Fig 10 show that, at 6 hours, the IL-la-stimulated increase in '=I-TNF-a specific binding can be wholly blocked for by utr-l, the anti-75-kD receptor antibody, with no apparent contribution from the 55-kD receptor. Even at 12 and 24 hours, when receptor numbers are returning to control levels, a greater portion of '*'I-TNF-a binding is blocked by the anti-75-kD receptor antibody than the anti-55-kD receptor antibody. Thus, these results show that the L-la-induced increase in '*'I-TNF-a specific binding is a result of increased expression of the 75-kD receptor.
DISCUSSION
These results show that L -l a induces the increased expression of TNF receptors on CDCL cells, a process that proceeds in parallel with the synergistic induction of G-CSF and GM-CSF mRNA accumulation and protein secretion by these cells.
The kinetics of synergistic induction of growth factor mRNA were very similar to the kinetics we had previously observed for the synergistic secretion of G-CSF and GM-CSF protein." After 12 hours of L -l a m -a costimulation, the mRNA levels were only additive compared with the individual induction for either cytokine alone. Synergistic levels were evident after 24 hours of costimulation. The degree of mRNA induction in L-1 a/TNF-a -treated CDCL cells was 15-fold and 18-fold greater than the additive levels induced by the two cytokines alone for GM-CSF and G-CSF mRNAs, respectively. By comparison, the absolute increase in growth factor mRNA in IL-la/TNF-a-treated cells compared with the level in untreated cells was 3,000-fold and 120,000-fold for GM-CSF and G-CSF, respectively. The difference between the absolute increase in G-CSF mRNA compared with GM-CSF is caused, in part, by the constitutive expression of GM-CSF mRNA in uninduced cells, whereas the G-CSF message was not detected in uninduced cells. This finding agrees with our earlier observation of constitutive secretion of GM-CSF into the culture supernatant, but not G-CSF. However, the constitutive secretion and expression of the GM-CSF protein and mRNA and the I L -l a m -a synergistic induction of both these components notwithstanding, the large magnitude of the synergistic induction of the G-CSF protein and mRNA suggests that G-CSF is likely a primary target of synergistic amplification. Cycloheximide blocked the synergistic induction of GM-CSF mRNA by IL-la and TNF-a, suggesting a requirement for new protein synthesis. Interestingly, the treatment of ILla-stimulated CDCL cells with cycloheximide resulted in nearly a sixfold increase in steady-state mRNA compared with L-la-stimulated cells not treated with cycloheximide. However, the net effect of costimulation in the presence of U Fig 7. Effect of CHX on IL-la induction of TNF recept ors. CDCL stromal cells were treated with IL-la and ynclfic MndInO of ' ZS-TNF-a was determined aftar 6 hours, as prdoudy descri bed. CHX (20 pg/mL) was added t o a r.plicate sot of IL-la--cultures after 4.5 hours and after a Sminute treatment with CHX in the presence of IL-la (cultures were treated with IL-la for e total of 6 hours!, apedfic binding o f '"l-TNF-a we8 determined U prdously describad. Spedfii binding of '9-TNF-u to cutturn that were not treated with IL-la or CHX was d e t e r m i n e d U wdl and usad as control. Bars represent the mean of triplicate determinations.
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Enprlrnenlal Design
Culturn Supsmalilnts CDCL cells express both forms of TNF receptors. The MoAbs htr-9 and u t r -l , which specifically bind the p55 end p75 TNF receptors. respectively, were used to block binding of '"I-TNF-a to TNF receptors on the surface of CDCL cells. CDCL cultures ware preincubated for 90 minutes with a saturating amount of Mr-9 or utr-l (l0 pgimL) before incubation for 90 minutes more with '"I-TNF-(r (8.6 pmollL). 'IsI-TNF-(r specific binding was determined as described in Materials and Methods. '9-TNF-a specific binding to control cultures, which were incubated with '"I-TNF-a without preincubation with antibody, was also determined. Each data point represents the mean f SD of triplicate determinations. After cultures were further incubated in the presence of IL-la plus TNF-a for 72 hours. the culture supernatants were assayed for GM-CSF (B) and G-CSF (Cl by ELSA. A set of replicate cultures were treated with IL-la plus TNF-a for the entire 96-hour period and used as control. Data are given as percent of control and each bar represents the mean triplicate cultures.
tion to the reports of TNF upregulating the expression of receptors of other hormones, the observation that IL-1 a was a vastly more potent inducer of growth factor protein and mRNA than TNF-a suggested that the pathway that mediates the IL-la signal was the likely pathway being amplified. Despite these reports of TNF-a influencing receptor expression of other cytokines, we found that CDCL stromal cells that had been treated with TNF-a for various lengths of time up to 24 hours resulted in no significant change in either IL-1 receptors numbers or ligand binding affinity. It is unlikely that the 20% increase in '251-IL-la specific binding observed after 24 hours of TNFa treatment is a component of IL-la/TNF-a synergistic induction of GM-CSF and G-CSF because it occurs well after the initial detection of synergistic levels of growth factors in the culture supernatant and the synergistic increase in growth factor &A.
However, treatment of CDCL cells with IL-la for various lengths of time had a marked effect on expression of TNF receptors. The effect of IL-la on TNF receptors was biphasic, initially causing a 30% decrease after 3 hours of IL-1 treatment followed immediately by an increase of up to threefold above the expression in untreated cells after 6 hours. Our observation of an initial decrease in TNF receptors in response to treatment with IL-I is similar to the findings of Holtmann and Walla~h,'~ who reported that IL-1 downregulated TNF receptors on the surface of foreskin fibroblasts and cells from SV-80 and Hela cell lines. However, unlike the findings by Holtmann and Wallach. the decrease described here was relatively transient compared with the 20-hour duration they reported. More significantly though, the decrease they described was not followed by an increase in TNF receptors. IL-la affected only the number of TNF receptors on the cell surface, but had no effect on receptor ligand affinity compared with untreated cells.
The marked upregulation of TNF receptors in response to IL-la before the detection of synergistic increases in growth factor secretion and mRNA suggest that an increased sensitivity to TNF-a by CDCL cells via receptor induction might be a molecular component in IL-la/TNF-a synergy. The results of a kinetic experiment that compared the time course of synergistic secretion of growth factors into the culture supernatant and the time course of IL-la induction of TNF receptors and gradual return to baseline, showed that the occurrence of the two events are closely paralleled. This result suggests that increased expression of TNF receptors may be a prerequisite to IL-la/TNF-a synergism in CDCL stromal cells. This hypothesis is further supported by the observation that inhibition of IL-la induction of TNF receptor by cycloheximide also blocks the synergistic induction of growth factor mRNA. Taken together, these results indicate that protein synthesis at the point of TNF receptor induction is necessary for I L -l a m -a synergism. Antibody-blocking studies showed that CDCL cells bear both the p55 and p75 isoforms of the TNF receptor. However, the increase in TNF receptor induced by &la appears to be largely confined to the p75 receptor. These results are similar to those of Winzen et al?' who found that recovery of downregulated TNF receptors on IL-la-and TNl-atreated SV-80 cells to basal levels occurs via replacement of lost p55 receptors via p75 receptors, which were themselves not detectable on uninduced SV-80 ceiis.
One interesting aspect of TNF-anL-1~1 interaction is that the magnitude of the synergistic increases in GM-CSF and G-CSF mRNA levels and protein secretion are far higher than the observed increase in TNF receptors in response to treatment with IL-la per se. This disproportionality may indicate that there is an amplification in the cellular response signal to increased TNF receptor expression. Such an apparently disproportional relationship between receptor numbers and occupancy, on the one hand, and cellular response on the other has been widely observed in other ligand-receptor systems.26-28 Thus, the primary role of &la in the synergy mechanism may be to potentiate the TNF receptor-associated signal transduction pathway, the first step of which is TNF ligand-receptor binding.
The findings presented here indicate a novel interaction between =-la and TNl-a in BM stromal cells and suggest that this interaction might underlie the unique role these cells play in the support of hematopoiesis within the BM microenvironment. In other cell types, TNF has been found to both downregulate and upregulate receptor~,2"~~ whereas in the CDCL cells, we found that TNF-a had no effect on IL-I receptors. Conversely, we are aware of only one other system where cross-regulation of receptors between IL-1 and TNF has been documented, in which Holtmann and W a l i a c i~*~.~~ showed that fL-l downregulated expression of TNF receptors by foreskin fibroblasts, SV-80, and Hela cell lines. Thus, the interactions between the IL-1 and TNF pathways observed in BM stromal cells could be relatively tissue specific. Therefore, because IL-l and TNF are cytokines that are primarily produced by monocyte-macrophages during conditions of immune response, synergy between IL-I and TNF in stimulating G-CSF and GM-CSF production by marrow stromal cells might be a relatively specific local mechanism for amplifying the immune response in the marrow microenvironment.
Development of a better understanding of the mechanism for IL-UTNF synergism is further challenged in this instance by the possibility of different but coordinate mechanisms for GM-CSF and G-CSF induction. Thus, it appears that development of a more complete understanding of the molecular mechanism underlying IL-1mNF synergism would likely require an investigation into the rebpective signal transduction pathways as well as the factors involved in gene activation. Amplification of one or both cytokine signal transduction pathways as a result of signal cross-regulation could provide an additional level of control for basal producFor personal use only. on June 3, 2017. by guest www.bloodjournal.org From tion of myeloid-CSF versus production under a stressed state, eg, immune response, in the marrow microenvironment.
In summary, these data show that IL-la and TNF-a synergize to stimulate the mRNA accumulation and protein secretion of G-CSF and GM-CSF by BM CDCL cells. This synergy requires new protein synthesis, whereas additive effects of IL-la and TNF-a on myeloid CSFs do not. This synergistic stimulation is preceded by the induction of cell surface TNF receptors, which is a direct result of IL-la treatment. Taken together, these data suggest a novel pathway of cytokine interaction that may explain the apparently redundant roles of IL-la and TNF-a in myelopoiesis by identifying their potent biochemical synergy at the level of the BM stromal cell.
